Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020193 | 0.84 | MAPK14 (0.50) | SIGMAR1MAPK14ABL1BCRRXFP1 | |
| SCHEMBL3784641 | 0.81 | MAPK14 (0.55) | SIGMAR1MAPK14ABL1BCRALDH1A1 | |
| SCHEMBL14653892 | 0.76 | SIGMAR1 (0.75) | SIGMAR1 | |
| SCHEMBL19700806 | 0.75 | POLB (0.55) | MAPK14ABL1BCRALDH1A1CYP1A2 | |
| SCHEMBL14636048 | 0.74 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL14646780 | 0.74 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL14636723 | 0.74 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL14646784 | 0.74 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL13020229 | 0.73 | KDM4E (0.49) | SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14630925 | 0.73 | SIGMAR1 (0.98) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SIGMAR1 1727/4885MAPK14 1189/4885ABL1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.